Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes

Cited by (1,000)

Items 401–500 of 1,000

1. Basic Research in Kidney Cancer
   Egbert Oosterwijk, W. Kimryn Rathmell, Kerstin Junker, Angela Rose Brannon, Frédéric Pouliot, David S. Finley, Peter Mulders, Ziya Kırkalı, Hirotsugo Uemura, Arie S. Belldegrun · 2011 · European Urology
2. Genome-wide CpG island methylation analysis implicates novel genes in the pathogenesis of renal cell carcinoma
   Christopher J. Ricketts, Mark R. Morris, Dean Gentle, Mick D. Brown, Naomi C. Wake, Emma Roisin Woodward, Noel William Clarke, Farida Latif, Eamonn Richard Maher · 2012 · Epigenetics
3. The Application of Genome-Wide 5-Hydroxymethylcytosine Studies in Cancer Research
   John P. Thomson, Richard R. Meehan · 2016 · Epigenomics
4. Renal Cell Carcinoma: Molecular Aspects
   Aman Kumar, Niti Kumari, Vinny Gupta, Rajendra Prasad · 2017 · Indian Journal of Clinical Biochemistry
5. Expression of the PTTG1 Oncogene Is Associated with Aggressive Clear Cell Renal Cell Carcinoma
   Bill Wondergem, Zhongfa Zhang, Dachuan Huang, Choon Kiat Ong, Julie M. Koeman, David Van't Hof, David Petillo, Aikseng Ooi, JOHN G. ANEMA, Brian R. Lane et al. · 2012 · Cancer Research
6. The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer
   Lili Liao, Joseph R. Testa, Haifeng Yang · 2015 · Cancer Genetics
7. Aberrant promoter hypermethylation ofPBRM1,BAP1,SETD2,KDM6Aand other chromatin-modifying genes is absent or rare in clear cell RCC
   Ilsiya Ibragimova, Marie E. Maradeo, Essel Dulaimi, Paul Cairns · 2013 · Epigenetics
8. Conditional inactivation of the mouse von Hippel–Lindau tumor suppressor gene results in wide-spread hyperplastic, inflammatory and fibrotic lesions in the kidney
   Tracy L. Pritchett, Hannah L. Bader, Joel Henderson, Tien Hsu · 2014 · Oncogene
9. Dysregulation of the Repressive H3K27 Trimethylation Mark in Head and Neck Squamous Cell Carcinoma Contributes to Dysregulated Squamous Differentiation
   Orla Margaret Gannon, Lilia Merida de Long, Liliana Endo‐Munoz, Mehlika H. Hazar-Rethinam, Nicholas Andrew Saunders · 2012 · Clinical Cancer Research
10. TERT promoter mutations in clear cell renal cell carcinoma
    Md. Ismail Hosen, P. Sivaramakrishna Rachakonda, Barbara Heidenreich, Raviprakash Tumkur Sitaram, Börje Ljungberg, Göran Roos, Kari Hemminki, Rajiv Kumar · 2014 · International Journal of Cancer
11. Renal cell carcinoma: new insights and challenges for a clinician scientist
    Roman A. Shingarev, Edgar A. Jaimes · 2017 · American Journal of Physiology-Renal Physiology
12. Targeting HIF2 in Clear Cell Renal Cell Carcinoma
    Hyejin Cho, William G. Kaelin · 2016 · Cold Spring Harbor Symposia on Quantitative Biology
13. Network-Guided Analysis of Genes with Altered Somatic Copy Number and Gene Expression Reveals Pathways Commonly Perturbed in Metastatic Melanoma
    Armand Valsesia, Donata Rimoldi, Danielle Martinet, Mark R. Ibberson, Paola Benaglio, Manfredo Quadroni, Patrice Waridel, Muriel Gaillard, Mireille Pidoux, Blandine Rapin et al. · 2011 · PLoS ONE
14. NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy
    Gary R. Hudes, Michael Anthony Carducci, Toni K. Choueiri, Peg Esper, Eric Jonasch, Rashmi Kumar, Kim Allyson Margolin, Marc Dror Michaelson, Robert John Motzer, Роберто Пили et al. · 2011 · Journal of the National Comprehensive Cancer Network
15. The role of histone H3K36me3 writers, readers and erasers in maintaining genome stability
    Asmita Sharda, Timothy C. Humphrey · 2022 · DNA repair
16. Epigenetic drugs against cancer: an evolving landscape
    Antonella Di Costanzo, Nunzio Del Gaudio, Antimo Migliaccio, Lucia Altucci · 2014 · Archives of Toxicology
17. Mutation analysis of HIF prolyl hydroxylases (PHD/EGLN) in individuals with features of phaeochromocytoma and renal cell carcinoma susceptibility
    Dewi Astuti, Christopher J. Ricketts, Rasheduzzaman Chowdhury, M.A. McDonough, Dean Gentle, Gail A. Kirby, Susanne Schlisio, Rajappa S. Kenchappa, B. D. Carter, William G. Kaelin et al. · 2010 · Endocrine Related Cancer
18. KMT2D Mutation Is Associated With Poor Prognosis in Non–Small-Cell Lung Cancer
    Fatemeh Ardeshir‐Larijani, Priyanka Bhateja, Mary Beth Lipka, Neelesh Sharma, Pingfu Fu, Afshin Dowlati · 2018 · Clinical Lung Cancer
19. Proteomic analysis of formalin‐fixed paraffin‐embedded renal tissue samples by label‐free MS: Assessment of overall technical variability and the impact of block age
    Rachel A. Craven, David Allan Cairns, Alexandre Zougman, Patricia Harnden, Peter John Selby, Rosamonde Elizabeth Banks · 2012 · PROTEOMICS - CLINICAL APPLICATIONS
20. Loss of PBRM1 and BAP1 expression is less common in non–clear cell renal cell carcinoma than in clear cell renal cell carcinoma
    Thai H. Ho, Payal Kapur, Richard Wayne Joseph, Daniel Serie, Jeanette E. Eckel‐Passow, Mansi A. Parasramka, John C. Cheville, Kevin J. Wu, Eugene P. Frenkel, Dinesh Rakheja et al. · 2014 · Urologic Oncology Seminars and Original Investigations
21. Molecular Diagnostic Trends in Urological Cancer: Biomarkers for Non-Invasive Diagnosis
    Virginia Urquidi, Charles Joel Rosser, Steven Goodison · 2012 · Current Medicinal Chemistry
22. Intratumoral heterogeneity in kidney cancer
    Christopher J. Ricketts, William Marston Linehan · 2014 · Nature Genetics
23. Cilia and cilia-associated proteins in cancer
    Tamina Seeger‐Nukpezah, Joy L. Little, Victoria Serzhanova, Erica A. Golemis · 2013 · Drug Discovery Today Disease Mechanisms
24. Epigenetics of Kidney Cancer And Bladder Cancer
    Amanda M. Hoffman, Paul Cairns · 2011 · Epigenomics
25. What are we learning from the cancer genome?
    Eric A. Collisson, Raymond Jaihyun Cho, Joe W. Gray · 2012 · Nature Reviews Clinical Oncology
26. DNA Methylation Biomarkers Predict Progression-Free and Overall Survival of Metastatic Renal Cell Cancer (mRCC) Treated with Antiangiogenic Therapies
    Inga Peters, Natalia Dubrowinskaja, Mahmoud Abbas, Christoph Alexander Seidel, Michael Kogosov, Ralph Scherer, Kai Gebauer, Axel S. Merseburger, Markus Antonius Kuczyk, Viktor Grünwald et al. · 2014 · PLoS ONE
27. Group I p21-Activated Kinases (PAKs) Promote Tumor Cell Proliferation and Survival through the AKT1 and Raf–MAPK Pathways
    Craig W. Menges, Eleonora Sementino, Jacqueline N. Talarchek, Jinfei Xu, Jonathan Chernoff, Jeffrey R. Peterson, Joseph R. Testa · 2012 · Molecular Cancer Research
28. Epigenetic regulation in RCC: opportunities for therapeutic intervention?
    James Larkin, Xin Yi Goh, Marcus Hermann Friedrich Vetter, Lisa M. Pickering, Charles Swanton · 2012 · Nature Reviews Urology
29. Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer
    In‐Kyu Kim, Justine N. McCutcheon, Guanhua Rao, Stephen V. Liu, Yves G. Pommier, Marcin Tomasz Skrzypski, Yu-Wen Zhang, Giuseppe Giaccone · 2018 · Oncogene
30. Kinetic characterization of human histone H3 lysine 36 methyltransferases, ASH1L and SETD2
    Mohammad S. Eram, Ekaterina Kuznetsova, Fengling Li, Evelyne Lima‐Fernandes, Steven Kennedy, Irene Chau, C.H. Arrowsmith, Matthieu Schapira, Masoud Vedadi · 2015 · Biochimica et Biophysica Acta (BBA) - General Subjects
31. The MLL3/4 H3K4 methyltransferase complex in establishing an active enhancer landscape
    Wang, Lan-Hsin, Aberin, Marvin Angelo E., Wu, Sean, Wang, Shu-Ping · 2021 · Biochemical Society Transactions
32. Coordinated demethylation of H3K9 and H3K27 is required for rapid inflammatory responses of endothelial cells
    Yoshiki Higashijima, Yusuke Matsui, Teppei Shimamura, Ryo Nakaki, Nao Nagai, Shuichi Tsutsumi, Yohei Abe, Verena M. Link, Mizuko Osaka, Masayuki Yoshida et al. · 2020 · The EMBO Journal
33. SETD2: from chromatin modifier to multipronged regulator of the genome and beyond
    Thom M. Molenaar, Fred van Leeuwen · 2022 · Cellular and Molecular Life Sciences
34. Cellular epigenetic stability and cancer
    Peter Sarkies, Julian E. Sale · 2012 · Trends in Genetics
35. Hyperactivated JNK Is a Therapeutic Target in pVHL-Deficient Renal Cell Carcinoma
    Jiabin An, Huiren Liu, Clara E. Magyar, Yanchuan Guo, Mysore S. Veena, Eri S. Srivatsan, Jiaoti Huang, Matthew B. Rettig · 2013 · Cancer Research
36. SETD2 Haploinsufficiency for Microtubule Methylation Is an Early Driver of Genomic Instability in Renal Cell Carcinoma
    Yun-Chen Chiang, In-Young Park, Esteban Terzo, Durga Nand Tripathi, Frank M. Mason, Catherine C. Fahey, Menuka Karki, Charles Bradley Shuster, Bo-Hwa Sohn, Pratim Chowdhury et al. · 2018 · Cancer Research
37. Reliable gene mutation prediction in clear cell renal cell carcinoma through multi-classifier multi-objective radiogenomics model
    Xi Chen, Zhiguo Zhou, Raquibul Hannan, Kimberly M. Thomas, Iván Pedrosa, Payal Kapur, James Brugarolas, Xuanqin Mou, Jing Wang · 2018 · Physics in Medicine and Biology
38. Renal carcinoma associated with a novel succinate dehydrogenase A mutation: a case report and review of literature of a rare subtype of renal carcinoma
    Yasemin Özlük, Diana Taheri, Andrés Matoso, Öner Şanlı, Neslihan Kayisoglu Berker, Evgeny Yakirevich, Sohail Balasubramanian, Jeffrey S. Ross, Siraj Mahamed Ali, George Jabboure Netto · 2015 · Human Pathology
39. Alterations of the spindle checkpoint pathway in clinicopathologically aggressive C p G island methylator phenotype clear cell renal cell carcinomas
    Eri Arai, Masahiro Gotoh, Ying Tian, Hiromi Sakamoto, Masaya Ono, Akio Matsuda, Yoriko Takahashi, Sayaka Miyata, Hirohiko Totsuka, Suenori Chiku et al. · 2015 · International Journal of Cancer
40. microRNA-21-induced dissociation of PDCD4 from rictor contributes to Akt-IKKβ-mTORC1 axis to regulate renal cancer cell invasion
    Amit Bera, Falguni Das, Nandini Ghosh‐Choudhury, Balakuntalam S. Kasinath, Hanna E. Abboud, Goutam Ghosh Choudhury · 2014 · Experimental Cell Research
41. Prognostic Value of SETD2 Expression in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors
    Jiajun Wang, Li Liu, Yang Qu, Wei Xi, Yu Xia, Qi Bai, Ying Xiong, Qilai Long, Jiejie Xu, Jianming Guo · 2016 · The Journal of Urology
42. Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma
    Brandon J. Manley, Emily Craig Zabor, Jozefina Casuscelli, Daniel M. Tennenbaum, Almedina Redzematovic, Maria F. Becerra, Nicole E. Benfante, Yusuke Sato, Teppei Morikawa, Haruki Kume et al. · 2016 · European Urology Focus
43. Clear cell carcinomas of the ovary and kidney: clarity through genomics
    Jennifer Xiao Ye Ji, Yi Kan Wang, Dawn R. Cochrane, David D. Huntsman · 2018 · The Journal of Pathology
44. Genomics of adult and pediatric solid tumors.
    Zahraa Rahal, Farah Abdulhai, Humam N. Kadara, Raya Hamad Saab · 2018 · Europe PMC (PubMed Central)
45. Mutations leading to constitutive active gp130/JAK1/STAT3 pathway
    Camilla Pilati, Jessica Zucman‐Rossi · 2015 · Cytokine & Growth Factor Reviews
46. Epigenomics of clear cell renal cell carcinoma: mechanisms and potential use in molecular pathology.
    Tianying Xing, Huiying He · 2016 · Europe PMC (PubMed Central)
47. H3K36 Methyltransferases as Cancer Drug Targets: Rationale and Perspectives for Inhibitor Development
    David S. Rogawski, Jolanta E. Grembecka, Tomasz Cierpicki · 2016 · Future Medicinal Chemistry
48. The Identification of Immunological Biomarkers in Kidney Cancers
    Antonio Lopez-beltran B, Vanessa Henriques, Alessia Cimadamore, Matteo Santoni, Liang Cheng C, Thomas Gevaert, Ana Blanca, Francesco Massari, Marina Scarpelli, Rodolfo Montironi · 2018 · Frontiers in Oncology
49. Heterogeneous Effects of Direct Hypoxia Pathway Activation in Kidney Cancer
    Rafik A. Salama, Norma Masson, Peter D. Simpson, Lina Katrin Sciesielski, Min Sun, Ya‐Min Tian, Peter John Ratcliffe, David Robert Mole · 2015 · PLoS ONE
50. A Non-Active-Site SET Domain Surface Crucial for the Interaction of MLL1 and the RbBP5/Ash2L Heterodimer within MLL Family Core Complexes
    Stephen A. Shinsky, Michael Hu, Valarie E. Vought, Sarah Boon Hsi Ng, Michael J. Bamshad, Jay Shendure, Michael S. Cosgrove · 2014 · Journal of Molecular Biology
51. Neurofilament Heavy polypeptide CpG island methylation associates with prognosis of renal cell carcinoma and prediction of antivascular endothelial growth factor therapy response
    Natalia Dubrowinskaja, Kai Gebauer, Inga Peters, Jörg Hennenlotter, Mahmoud Abbas, Ralph Scherer, Hossein Tezval, Axel S. Merseburger, Arnulf Stenzl, Viktor Grünwald et al. · 2014 · Cancer Medicine
52. Distinct molecular profile of diffuse cerebellar gliomas
    Masashi Nomura, Akitake Mukasa, Genta Nagae, Shogo Yamamoto, Kenji Tatsuno, Hiroki Ueda, Shiro Fukuda, Takayoshi Umeda, Tomonari Suzuki, Ryohei Otani et al. · 2017 · Acta Neuropathologica
53. Recent advances in pathway-targeted cancer drug therapies emerging from cancer genome analysis
    Robert L. Yauch, Jeff Settleman · 2012 · Current Opinion in Genetics & Development
54. Genome-wide CRISPR screens using isogenic cells reveal vulnerabilities conferred by loss of tumor suppressors
    Xu Feng, Mengfan Tang, Merve Dede, Dan Su, Guangsheng Pei, Dadi Jiang, Chao Wang, Zhen Chen, Mi Li, Litong Nie et al. · 2022 · Science Advances
55. DNA Methylation-mediated Repression of miR-941 Enhances Lysine (K)-specific Demethylase 6B Expression in Hepatoma Cells
    Pei-Pei Zhang, Xiang-ling Wang, Wei Zhao, Bing Qi, Qian Yang, Hai-Ying Wan, Ze-Yu Shuang, Min Liu, Xin Li, Shengping Li et al. · 2014 · Journal of Biological Chemistry
56. Toward personalized cancer nanomedicine – past, present, and future
    Alexander H. Stegh · 2012 · Integrative Biology
57. High MLL2 expression predicts poor prognosis and promotes tumor progression by inducing EMT in esophageal squamous cell carcinoma
    Abulajiang Abudureheman, Julaiti Ainiwaer, Zhichao Hou, Madiniyat Niyaz, Abdugheni Turghun, Ayshamgul Hasim, Haiping Zhang, Xiaomei Lu, Ilyar Sheyhidin · 2018 · Journal of Cancer Research and Clinical Oncology
58. Genomics and clinical correlates of renal cell carcinoma
    Thomas J. Mitchell, Sabrina Helena Rossi, Tobias Klatte, Grant Duncan Stewart · 2018 · World Journal of Urology
59. Hypoxia-driven epigenetic regulation in cancer progression: A focus on histone methylation and its modifying enzymes
    Iljin Kim, Jong‐Wan Park · 2020 · Cancer Letters
60. Significance of KDM6A mutation in bladder cancer immune escape
    Xingxing Chen, Xuehua Lin, Guofu Pang, Jian Deng, Qun Xie, Zhengrong Zhang · 2021 · BMC Cancer
61. Renal cell carcinoma
    Daniel Su, Lambros Stamatakis, Eric A. Singer, Ramaprasad Srinivasan · 2014 · Current Opinion in Oncology
62. RCDB: Renal Cancer Gene Database
    Jayashree Ramana · 2012 · BMC Research Notes
63. Histone demethylase KDM4C regulates sphere formation by mediating the cross talk between Wnt and Notch pathways in colonic cancer cells
    Shinzo Yamamoto, Keisuke Tateishi, Yotaro Kudo, Keisuke Yamamoto, Takayuki Isagawa, Genta Nagae, Takuma Nakatsuka, Yoshinari Asaoka, Hideaki Ijichi, Yoshihiro Hirata et al. · 2013 · Carcinogenesis
64. The Role of Epigenetics in the Progression of Clear Cell Renal Cell Carcinoma and the Basis for Future Epigenetic Treatments
    J.C. Angulo, Claudia Manini, Jose Ignacio Lopez, Angel Pueyo, Begoña Colás, Santiago Ropero · 2021 · Cancers
65. PHF6 Degrees of Separation: The Multifaceted Roles of a Chromatin Adaptor Protein
    Matthew A. M. Todd, Danton Ivanochko, David J. Picketts · 2015 · Genes
66. The Molecular Biology of Renal Cell Carcinoma
    Stephen J. O’Keefe, Katherine L. Nathanson, W. Kimryn Rathmell · 2013 · Seminars in Oncology
67. Molecular pathways in renal cell carcinoma
    Daniel Su, Eric A. Singer, Ramaprasad Srinivasan · 2015 · Current Opinion in Oncology
68. A Transposon-Based Analysis of Gene Mutations Related to Skin Cancer Development
    Rita M. Quintana, Adam J. Dupuy, Ana Bravo, M. Casanova, Josefa P. Alameda, Angustias Page, Miguel Sánchez-Viera, Ángel Ramı́rez, Manuel Navarro · 2012 · Journal of Investigative Dermatology
69. DNA methylation profiling reveals novel diagnostic biomarkers in renal cell carcinoma
    Brittany N. Lasseigne, Todd C. Burwell, Mohini A. Patil, Devin Absher, James D. Brooks, R Myers · 2014 · BMC Medicine
70. SETD2-mediated crosstalk between H3K36me3 and H3K79me2 in MLL-rearranged leukemia
    Jiachen Bu, A Chen, Xiaomei Yan, Fuhong He, Yunzhu Dong, Yuanli Zhou, Jianzhong He, D Zhan, Peipei Lin, Yoshihiro Hayashi et al. · 2017 · Leukemia
71. Whole-Exome Sequencing of Matched Primary and Metastatic Papillary Thyroid Cancer
    Tariq Masoodi, Abdul K. Siraj, Sarah Siraj, Saud Azam, Zeeshan Qadri, Wafaa N. Albalawy, Sandeep Kumar Parvathareddy, Saif S. Al-Sobhi, Fouad Al‐Dayel, Fowzan Sami Alkuraya et al. · 2019 · Thyroid
72. Mutations in Critical Domains Confer the Human mTOR Gene Strong Tumorigenicity*
    Avaniyapuram Kannan Murugan, Ali Saeed Alzahrani, Mingzhao Xing · 2013 · Journal of Biological Chemistry
73. Current Limitations And Future Opportunities For Epigenetic Therapies
    Fanny Cherblanc, Nadine Chapman‐Rothe, Robert Eldon Brown, Matthew John Fuchter · 2012 · Future Medicinal Chemistry
74. Radiogenomics in renal cell carcinoma
    Francesco Alessandrino, Atul Bhanudas Shinagare, Dominick Bossé, Toni K. Choueiri, Katherine Maragaret Krajewski · 2018 · Abdominal Radiology
75. Cancer-derived UTX TPR mutations G137V and D336G impair interaction with MLL3/4 complexes and affect UTX subcellular localization
    Hiroyuki Kato, Kaori Asamitsu, Wendi Sun, Shojiro Kitajima, Naoko Yoshizawa-Sugata, Takashi Okamoto, Hisao Masai, Lorenz Poellinger · 2020 · Oncogene
76. Cryo-EM structure of SETD2/Set2 methyltransferase bound to a nucleosome containing oncohistone mutations
    Yingying Liu, Yanjun Zhang, Han Xue, Cao Mi, Guohui Bai, Zongkai Mu, Yanli Yao, Shuyang Sun, Dong Fang, Jing Huang · 2021 · Cell Discovery
77. Multiomics characterization and verification of clear cell renal cell carcinoma molecular subtypes to guide precise chemotherapy and immunotherapy
    Jialin Meng, Aimin Jiang, Xiaofan Lu, Di Gu, Qintao Ge, Suwen Bai, Yundong Zhou, Jun Zhou, Zongyao Hao, Fangrong Yan et al. · 2023 · iMeta
78. Molecular aspects of cyclophilins mediating therapeutic actions of their ligands
    Andrzej Gałat, Jacqueline Búa · 2010 · Cellular and Molecular Life Sciences
79. Laser capture microdissection–reduced representation bisulfite sequencing (LCM-RRBS) maps changes in DNA methylation associated with gonadectomy-induced adrenocortical neoplasia in the mouse
    Maximiliaan Schillebeeckx, Anja Schrade, Ann‐Kathrin Löbs, Marjut Pihlajoki, David Brown Wilson, Robi David Mitra · 2013 · Nucleic Acids Research
80. PI3Kβ Inhibitor TGX221 Selectively Inhibits Renal Cell Carcinoma Cells with Both VHL and SETD2 mutations and Links Multiple Pathways
    Chenchen Feng, Yang Sun, Guanxiong Ding, Zhong Wu, Haowen Jiang, Lujia Wang, Qiang Ding, Hui Wen · 2015 · Scientific Reports
81. Identification of Molecular Tumor Markers in Renal Cell Carcinomas with TFE3 Protein Expression by RNA Sequencing
    Dorothee Pflueger, Andrea Sboner, Martina Storz, Jasmine Roth, Éva Compérat, Elisabeth Bruder, Mark A. Rubin, Peter Schraml, Holger Moch · 2013 · Neoplasia
82. HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase
    Abhishek A. Chakraborty, Eijiro Nakamura, Jun Qi, Amanda L. Creech, Jacob D. Jaffe, Joshiawa Paulk, Jesse S. S. Novak, Kshithija Nagulapalli, Samuel K. McBrayer, Glenn S. Cowley et al. · 2017 · Science Translational Medicine
83. Germline mutations of renal cancer predisposition genes and clinical relevance in Chinese patients with sporadic, early‐onset disease
    Junlong Wu, Hongkai Wang, Christopher J. Ricketts, Youfeng Yang, Maria J. Merino, Hailiang Zhang, Guohai Shi, Hualei Gan, William Marston Linehan, Yao Zhu et al. · 2018 · Cancer
84. GATA3 recruits UTX for gene transcriptional activation to suppress metastasis of breast cancer
    Wenqian Yu, Wei Huang, Yang Yang, Rongfang Qiu, Yi Zeng, Yongqiang Hou, Gancheng Sun, Hang Shi, Shuai Leng, Dandan Feng et al. · 2019 · Cell Death and Disease
85. The RNA N6-Methyladenosine Methyltransferase METTL3 Promotes the Progression of Kidney Cancer via N6-Methyladenosine-Dependent Translational Enhancement of ABCD1
    Yue Xi Shi, Yanliang Dou, Jianye Zhang, Jie Qi, Zijuan Xin, Mingxin Zhang, Yu Pei Xiao, Weimin Ci · 2021 · Frontiers in Cell and Developmental Biology
86. Structural and Functional Impact of Cancer-Related Missense Somatic Mutations
    Zhen Shi, John Moult · 2011 · Journal of Molecular Biology
87. Network of Cancer Genes (NCG 3.0): integration and analysis of genetic and network properties of cancer genes
    Matteo D’Antonio, Vera Pendino, Shruti Sinha, Francesca D. Ciccarelli · 2011 · Nucleic Acids Research
88. DNA methylation profiling distinguishes histological subtypes of renal cell carcinoma
    A Slater, Majed Saleh Alokail, Dean Gentle, Masahiro Yao, Gyula Kovács, Eamonn Richard Maher, Farida Latif · 2013 · Epigenetics
89. The methylation landscape of tumour metastasis
    Alicia Maria Cock-Rada, Jonathan B Weitzman · 2012 · Biology of the Cell
90. Adult Renal Cell Carcinoma
    Michelle S. Hirsch, Sabina Signoretti, Paola Dal Cin · 2015 · Surgical pathology clinics
91. Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies
    Jiancheng Zhou, Junhang Luo, Kaijie Wu, E-j Yun, Payal Kapur, R C Pong, Yuefeng Du, B. Wang, Craig Authement, Enrique Hernández et al. · 2016 · Oncogene
92. Radiomics and Artificial Intelligence for Renal Mass Characterization
    Meghan G. Lubner · 2020 · Radiologic Clinics of North America
93. Chromosome 9p deletion in clear cell renal cell carcinoma predicts recurrence and survival following surgery
    Ismail El‐Mokadem, Patricia Fitzpatrick, Jasper Bondad, Petra Rauchhaus, J Cunningham, Norman Pratt, S. Fleming, Ghulam Nabi · 2014 · British Journal of Cancer
94. Kidney cancer
    William Marston Linehan, W. Kimryn Rathmell · 2012 · Urologic Oncology Seminars and Original Investigations
95. Pathophysiological Response to Hypoxia — From the Molecular Mechanisms of Malady to Drug Discovery: Epigenetic Regulation of the Hypoxic Response via Hypoxia-Inducible Factor and Histone Modifying Enzymes
    Imari Mimura, Tetsuhiro Tanaka, Youichiro Wada, Tatsuhiko Kodama, Masaomi Nangaku · 2011 · Journal of Pharmacological Sciences
96. Renal cell carcinoma in children and adolescents
    Filippo Spreafico, Paola Collini, Monica Terenziani, Alfonso Vittorio Marchianò, Luigi Piva · 2010 · Expert Review of Anticancer Therapy
97. RNA-seq Reveals Aurora Kinase–Driven mTOR Pathway Activation in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma
    Sumanta Kumar Pal, Miaoling He, Tommy Richard Sun-wing Tong, Huiqing Wu, Xueli Liu, Clayton Lau, Jinhui Wang, Charles Warden, Xiwei Wu, Sabina Signoretti et al. · 2014 · Molecular Cancer Research
98. Decoding the Histone Code: Role of H3K36me3 in Mismatch Repair and Implications for Cancer Susceptibility and Therapy
    Guo‐Min Li · 2013 · Cancer Research
99. Setdb1, a novel interactor of ΔNp63, is involved in breast tumorigenesis
    Carla Regina, Mirco Compagnone, Angelo Peschiaroli, Anna Maria Lena, Margherita Annicchiarico‐Petruzzelli, Maria Cristina Piro, Gerry Melino, Eleonora Candi · 2016 · Oncotarget
100. KDM6A promotes imatinib resistance through YY1-mediated transcriptional upregulation of TRKA independently of its demethylase activity in chronic myelogenous leukemia
     Chengwan Zhang, Li Shen, Yifu Zhu, Ran Xu, Zhi-Kui Deng, Xiaoning Liu, Yihan Ding, Chunling Wang, Yuye Shi, Li-Ye Bei et al. · 2021 · Theranostics